DAX®15.568,73+0,16%TecDAX®3.717,94+0,99%Dow Jones 3034.975,40+0,11%Nasdaq 10015.006,95+0,31%
finanztreff.de

PRESS RELEASE: MagForce AG Supports World Brain -2-

| Quelle: Dow Jones Newsw... | Lesedauer etwa 8 min. | Text vorlesen Stop Pause Fortsetzen
PRESS RELEASE: MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications


DGAP-News: MagForce AG / Key word(s): Miscellaneous
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the
Deadliest Oncological Indications
2021-06-07 / 08:30
The issuer is solely responsible for the content of this announcement.
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the
Deadliest Oncological Indications
Berlin, Germany, and Nevada, USA, June 7, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a
leading medical device company in the field of nanomedicine focused on oncology, offering the NanoTherm Therapy System
for the treatment of brain tumors, supports World Brain Tumor Day on June 8^th, 2021 and informs about various virtual
patient events to raise awareness for this devastating disease.
"Though rare compared to other types of cancers, brain tumors, especially glioblastomas, are a devastating and mostly
fatal disease. Despite major advances in treatment modalities, malignant tumors of the brain remain largely incurable
and an unresolved therapeutic problem. At MagForce it is our mission to provide patients with a further treatment
option and make our innovative approach based on nanotechnology available all over the world," said Ben Lipps, CEO of
MagForce AG and MagForce USA, Inc. "Keeping in line with tradition, I am happy that MagForce once again has the
opportunity to support affiliated brain tumor centers in their numerous activities for brain tumor patients and their
caregivers on occasion of the World Brain Tumor Day."
Zwickau, Germany - Paracelsus Clinic Zwickau Hosts Patient Hotline "Meet a Professor"
In 2019, the Paracelsus Clinic Zwickau and MagForce announced their cooperation on the occasion of 20^th anniversary of
the World Brain Tumor Day, one of four clinics in Europe to offer MagForce's NanoTherm Therapy System for the treatment
of brain tumors. Headed by Prof. Dr. med. habil. Jan-Peter Warnke, the department of neurosurgery cares for
approximately 2,200 patients annually and performs an average of 1,500 surgeries per year, of which approximately 300
are primary gliomas.
This year, the Paracelsus Clinic Zwickau will host an open hotline "Meet a Professor" where patients will be able to
put forth any questions they may have regarding brain tumors and multiple treatment options. Prof. Dr. med. Habil.
Warnke and Christian Schürer, Assistant Physician and contact for the NanoTherm Therapy System at the Paracelsus Clinic
Zwickau, will be available from 9am to 3pm to answer questions on the subject of glioblastomas and the NanoTherm
Therapy as an alternative treatment option.
When: Tuesday, June 8th, 2021, 9am-3pm CEST
Phone: 0800-55-66-102
Lublin, Poland - Alivia Cancer Foundation, SPSK4 Hospital and MagForce Invite you to join their Infoline on the
Treatment of Brain Tumors Using the NanoTherm Therapy System
According to estimates, every fourth inhabitant of Poland is diagnosed with cancer during their lifetime, and every
fifth will die from it. Although recent years have brought about rapid progress in the knowledge of pathomechanisms
underlying each cancer, and cancer itself, contributing to many new drugs and therapies being launched onto the market,
access to effective treatment options in Poland remain limited. As a result, the average Pole has a lower chance to
survive 5 years with cancer compared to citizens of other European countries.
The Independent Public Clinical Hospital No. 4 (SPSK4) in Lublin, one of the leading brain treatment centers in Poland,
is the first hospital outside of Germany to offer MagForce's NanoTherm Therapy System as an additional treatment option
allowing Polish patients to receive treatment in their home country and provide faster access to the therapy for
patients from surrounding countries.
On occasion of the 2021 World Brain Tumor Day, the SPSK4 will host a free Infoline, supported by MagForce and Alivia
Cancer Foundation. Prof. Tomasz Trojanowski, Polish National Consultant for Neurosurgery and a member of the Scientific
Advisory Board of the Minister of Health of Poland, Prof. Radoslaw Rola, Head and Chairman of the Neurosurgery and
Paediatric Neurosurgery Departments, and Dr Jacek Wozniak, Specialist of the Center for Innovative Therapies, will be
available for a free consultation and answer all patient question regarding the NanoTherm Therapy System at SPSK4.
When: Tuesday, June 8^th at 9am-3pm (Dr. Jacek Wozniak) and 3pm-4pm CEST (Prof. Tomasz Trojanowski and Prof. Radoslaw
Rola)
Phone: +48 781887223
DGNC 2021, Virtual - MagForce is Main Sponsor of the Leading Conference in the Field of Neurosurgery
Taking place around the World Brain Tumor Day from June 6-9, the 72nd Annual Meeting of the German Society of
Neurosurgery (DGNC) held jointly with the Polish Society of Neurosurgeons will provide a virtual platform to present
scientific findings, discuss new innovative treatments and exchange information about the most recent research results
and future visions.
As main-sponsor, MagForce is excited to support this important event in the field of neurosurgery and represented with
a virtual booth, where MagForce representatives are available for questions regarding its NanoTherm Therapy System.
For more information on the 2021 DGNC Meeting programme, please click here.
About World Brain Tumor Day
Declared by the Deutsche Hirntumorhilfe (German Brain Tumour Association) in 2000 as an international commemoration
day, the World Brain Tumor Day is celebrated every year on June 8^th to raise awareness about brain tumours and inspire
hope for patients living with this disease. According to current information from the Deutsche Hirntumorhilfe^[i], each
year, more than 8,000 people are diagnosed with a primary brain tumor in Germany alone. Glioblastoma is the most common
and aggressive form of brain tumors in adults with an incidence, i.e. the number of new cases per year, of about three
patients per 100,000 people. Worldwide, over 700 new cases are recorded on a daily basis. Additionally, many other
types of cancer cause metastases in the brain, which are known as secondary brain tumors. Despite major advances in
treatment modalities, malignant tumors of the brain remain largely incurable and an unresolved therapeutic problem.
The NanoThermTherapy System for the Treatment of Brain Tumors
MagForce's NanoTherm Therapy System provides a novel, nanotechnology-based approach for the treatment of solid tumors
by introducing magnetic nanoparticles either directly into the tumor or into the resection cavity wall. At the
discretion of the attending neurosurgeon, the NanoTherm liquid containing the magnetic nanoparticles can be instilled
in the course of the tumor resection, keeping interventions to a minimum. The particles are subsequently heated by an
alternating magnetic field that allows targeted treatment by irreparably destroying, or weakening, cancer cells making
them more sensitive to concomitant radiotherapy or chemotherapy. These sessions generally take place over a three-week
period, either in an in-patient or out-patient setting depending on the patients condition, and are nearly completely
free of pain and discomfort. The limited time span required for the treatment makes the therapy highly predictable and
allows the patient to return to everyday life and regain significant quality of life as far and as soon as possible.
Since the particles remain at the site of instillation due to their special coating, the surrounding healthy tissue is
spared and the integration into multimodal therapy concepts are made possible.

MagForce AG was granted the European CE certificate ("European Certification") and thus the official approval of the
NanoTherm Therapy System for the treatment of brain tumors in Germany and all member states of the European Union.
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its
subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The
Group's proprietary NanoTherm therapy system enables the targeted treatment of solid tumors through the intratumoral
generation of heat via activation of superparamagnetic nanoparticles.
NanoTherm^(R), NanoPlan^(R), and NanoActivator^(R) are components of the therapy and have received EU-wide regulatory
approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are
trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list
Contact:
Barbara von Frankenberg
VP Communications & Investor Relations
T +49-30-308380-77
M bfrankenberg@magforce.com

Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms
such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such
forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a
variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these
forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct
them in case of developments, which differ from those, anticipated.
^[i] Deutsche Hirntumorhilfe, https://www.hirntumorhilfe.de/projekte/welthirntumortag1/

2021-06-07 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

(MORE TO FOLLOW) Dow Jones Newswires

June 07, 2021 02:31 ET ( 06:31 GMT)


The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange
EQS News ID: 1204695

End of News DGAP News Service

1204695 2021-06-07



Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1204695&application_name=news


(END) Dow Jones Newswires

June 07, 2021 02:31 ET ( 06:31 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:

Aktuelle Videos

HSBC Trading TV

Werbung

Trading-Tipp

Börsen & Märkte

US-Marktüberblick

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 31 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen